US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

18.68

+0.52002.86%

Post-market: 18.680.00000.00%16:53 EDT

Volume:364.88K

Turnover:6.87M

Market Cap:1.18B

PE:-8.39

High:19.50

Open:18.55

Low:18.36

Close:18.16

52wk High:20.25

52wk Low:7.80

Shares:63.19M

Float Shares:24.13M

Volume Ratio:0.63

T/O Rate:1.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.2271

EPS(LYR):-4.0460

ROE:-26.64%

ROA:-18.59%

PB:2.93

PE(LYR):-4.62

Loading ...

Overview Company News Filings

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Major Insider Move Signals Growing Confidence in Bicara Therapeutics

RA Capital Management Reports Acquisition of Bicara Therapeutics Common Shares

Bicara Therapeutics President and COO Ryan Cohlhepp Disposes of Common Shares

Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

THOMSON REUTERS

BUZZ-Bicara Therapeutics rises after $150 mln equity raise

Bicara Therapeutics Inc - Prices Public Offering of 7,175,000 Shares at $16.00 Each

THOMSON REUTERS

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

Bicara Therapeutics announces proposed offering of $150M in common stock

BRIEF-Bicara Therapeutics Announces Proposed Public Offering of Common Stock

Bicara Therapeutics Publishes Corporate Presentation on FICERA EGFR-Directed Antibody With TGF-β Ligand Trap in HPV-Negative HNSCC

Bicara Therapeutics to Participate in Upcoming Investor Conferences

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Accendra Health (ACH) and Travere Therapeutics (TVTX)

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Guardant Health (GH) and Bicara Therapeutics Inc. (BCAX)

Bicara: Best-in-Class Potential for Ficerafusp Alfa in First-Line HPV-Negative Head and Neck Cancer Supports Buy Rating and $30 Target

BRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCC

Bicara announces promising Phase 1b ficerafusp alfa results

Bicara Therapeutics Inc. Publishes Oral Presentation on Ficerafusp Alfa Plus Pembrolizumab in HPV-Negative Recurrent or Metastatic HNSCC

Ficerafusp Alfa 2000Mg Q2w Demonstrates Deep, Durable Responses in 1L R/M Hpv-Negative Hnscc and Supports Development of Less Frequent Dosing Regimen

THOMSON REUTERS

Bicara Therapeutics Inc: Plans to Develop a Loading and Every-Three-Week Maintenance Regimen for Ficerafusp Alfa, Pending Regulatory Alignment

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCAX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":18.68,"timestamp":1774468800000,"preClose":18.16,"halted":0,"volume":364879,"hourTrading":{"tag":"盘后","latestPrice":18.68,"preClose":18.68,"latestTime":"16:53 EDT","volume":4580,"amount":85554.4,"timestamp":1774471992419,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.028634361233480152,"floatShares":24134000,"shares":63193700,"eps":-2.227112,"marketStatus":"Post-Mkt","change":0.52,"latestTime":"03-25 19:15:38 EDT","open":18.55,"high":19.5,"low":18.36,"amount":6868547.974219999,"amplitude":0.062775,"askPrice":20.98,"askSize":100,"bidPrice":16,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-2.227112,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774483200000},"marketStatusCode":4,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":18.16,"preHourTrading":{"tag":"盘前","latestPrice":19.02,"preClose":18.16,"latestTime":"09:12 EDT","volume":557,"amount":10413.390158,"timestamp":1774444358936,"change":0.86,"changeRate":0.047357,"amplitude":0.043502},"postHourTrading":{"tag":"盘后","latestPrice":18.68,"preClose":18.68,"latestTime":"16:53 EDT","volume":4580,"amount":85554.4,"timestamp":1774471992419,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.626788,"impliedVol":0.4713,"impliedVolPercentile":0.5857},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":24134000,"roa":"-18.59%","roe":"-26.64%","lyrEps":-4.045991,"volumeRatio":0.626788,"shares":63193700,"dividePrice":0,"high":19.5,"amplitude":0.062775,"preClose":18.16,"low":18.36,"week52Low":7.8,"pbRate":"2.93","week52High":20.25,"institutionHeld":0,"latestPrice":18.68,"committee":-0.666667,"eps":-2.227112,"divideRate":0,"volume":364879,"delay":0,"ttmEps":-2.227112,"open":18.55,"prevYearClose":16.83,"prevWeekClose":18.41,"prevMonthClose":16.78,"prevQuarterClose":16.83,"fiveDayClose":18.41,"twentyDayClose":17.51,"sixtyDayClose":16.8,"earningDate":1774800000000,"earningTime":"盘前"},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"BCAX","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2025/12","expectedEps":-0.72,"defaultRemindTime":1774857600000,"name":null,"time":"Pre-Market","dateTimestamp":1774843200000,"actualEps":null},{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5},{"market":"US","date":"2025-05-13","symbol":"BCAX","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-27","symbol":"BCAX","fiscalQuarterEnding":"2024/12","expectedEps":-0.31,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.39}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2308,"buy":0.5385,"hold":0.2308,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5385,"analysts":13,"updateTime":1770868800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-03-24","current":-8.484082,"percent":0.446194,"low":-22.704836,"twenty":-15.102946,"median":-9.049024,"eighty":-6.581788,"high":-5.144536,"avg":-10.589675,"sd":4.605059,"marketCap":1194746808},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-06","current":-6.807115,"twenty":-15.936161,"median":-9.042505,"eighty":-6.562089,"marketCap":827207445},{"date":"2026-02-13","current":-6.338281,"twenty":-15.928174,"median":-8.933537,"eighty":-6.562089,"marketCap":770234217},{"date":"2026-02-20","current":-6.951372,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"marketCap":844737669},{"date":"2026-02-27","current":-8.759817,"twenty":-15.498177,"median":-8.759817,"eighty":-6.531952,"marketCap":1064501760},{"date":"2026-03-06","current":-9.890416,"twenty":-15.312456,"median":-8.853601,"eighty":-6.556096,"marketCap":1201893200},{"date":"2026-03-13","current":-10.269994,"twenty":-15.203584,"median":-8.927397,"eighty":-6.566815,"marketCap":1248019912},{"date":"2026-03-20","current":-10.045455,"twenty":-15.15052,"median":-9.021228,"eighty":-6.577062,"marketCap":1220733688},{"date":"2026-03-24","current":-9.831608,"twenty":-15.102946,"median":-9.049024,"eighty":-6.581788,"marketCap":1194746808}],"updateTime":1774454745362},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616555009","title":"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616555009","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616555009?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:30","pubTimestamp":1772631000,"startTime":"0","endTime":"0","summary":"BOSTON, March  04, 2026  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249366/0/en/Bicara-Therapeutics-Announces-Inducement-Grant-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2616239930","title":"Major Insider Move Signals Growing Confidence in Bicara Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2616239930","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616239930?lang=en_us&edition=fundamental","pubTime":"2026-03-03 10:09","pubTimestamp":1772503754,"startTime":"0","endTime":"0","summary":"New insider activity at Bicara Therapeutics Inc. ( ($BCAX) ) has taken place on March 2, 2026. Director Ra Capital Management, LLC has made a signi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-insider-move-signals-growing-confidence-in-bicara-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-insider-move-signals-growing-confidence-in-bicara-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2616369436","title":"RA Capital Management Reports Acquisition of Bicara Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616369436","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616369436?lang=en_us&edition=fundamental","pubTime":"2026-03-03 05:25","pubTimestamp":1772486719,"startTime":"0","endTime":"0","summary":"RA Capital Management, L.P. reported an acquisition of common shares of Bicara Therapeutics Inc. . The Form 4 was filed by multiple reporting owners, including RA Capital Management, L.P., RA Capital Healthcare Fund LP, Peter Kolchinsky, and Rajeev M. Shah, along with other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL3gPJy2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RA Capital Management Reports Acquisition of Bicara Therapeutics Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2614486220","title":"Bicara Therapeutics President and COO Ryan Cohlhepp Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614486220","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614486220?lang=en_us&edition=fundamental","pubTime":"2026-02-28 05:17","pubTimestamp":1772227072,"startTime":"0","endTime":"0","summary":"Ryan Cohlhepp, President and COO and a director of Bicara Therapeutics Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL6jQ9kW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Bicara Therapeutics President and COO Ryan Cohlhepp Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2614079175","title":"Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614079175","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614079175?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:29","pubTimestamp":1772141393,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM2BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2614751082","title":"BUZZ-Bicara Therapeutics rises after $150 mln equity raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2614751082","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614751082?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:02","pubTimestamp":1772024532,"startTime":"0","endTime":"0","summary":"BUZZ-Bicara Therapeutics rises after $150 mln equity raise** Bicara Therapeutics BCAX.O shares up 4.2% in premarket trading at $16.93 after $150 mln overnight follow-on priced** Boston, Massachusetts-based biopharma late Tues announced ~9.4 mln shares, including pre-funded warrants to buy 2.2 mln shares, at $16** Offering price is 1.5% discount to stock's last sale on Tues** Co intends to use net offering proceeds to support planned regulatory filing and commercial launch for ficerafusp alfa, its treatment for solid tumors, if approved, in the US, among other purposes** Morgan Stanley, TD Cowen, BofA, Cantor and Stifel joint bookrunners** Co has ~54.8 mln shares outstanding** Through Tues close, stock rose ~15% over the past week, leaving it down 3.5% YTD** 10 of 13 analysts rate the stock \"strong buy\" or \"buy\", 3 \"hold\"; median PT $30, per LSEG data** BCAX went public in Sept 2024 IPO priced at $18","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL6N3ZL0TZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BKVL7J92.USD","LU2023251221.USD","LU0557290698.USD","LU2133065610.SGD","BK4581","LU1720051017.SGD","LU0158827781.USD","LU1989772923.USD","LU1732799900.SGD","LU1989772840.SGD","LU0225283273.USD","LU1363072403.SGD","LU0528227936.USD","LU2111349929.HKD","LU0267386448.USD","LU0006306889.USD","BK4504","LU1074936037.SGD","LU2357305700.SGD","BK4139","LU0320765646.SGD","LU1791710400.SGD","LU2028103732.USD","LU0795875086.SGD","LU1668664300.SGD","LU0098860793.USD","IE00BZ1G4Q59.USD","LU0795875169.SGD","BK4534","LU0912757837.SGD","LU1244550221.USD","LU0106831901.USD","BK4127","LU0971096721.USD","LU0106261372.USD","LU2089283258.USD","LU2271345857.HKD","LU2347655156.SGD","LU1244550577.SGD","BK4516","BCAX","LU2089284900.SGD","LU0314104364.USD","LU1791710582.SGD","LU0158827948.USD","LU1720051108.HKD","LU1162221912.USD","LU0882574139.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"2614718787","title":"Bicara Therapeutics Inc - Prices Public Offering of 7,175,000 Shares at $16.00 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2614718787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614718787?lang=en_us&edition=fundamental","pubTime":"2026-02-25 12:13","pubTimestamp":1771992786,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA4FT1HD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2614771895","title":"Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2614771895","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614771895?lang=en_us&edition=fundamental","pubTime":"2026-02-25 12:13","pubTimestamp":1771992780,"startTime":"0","endTime":"0","summary":"BOSTON, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244229/0/en/Bicara-Therapeutics-Announces-Pricing-of-150-Million-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261372.USD","BK4588","LU1162221912.USD","LU1791710400.SGD","LU0912757837.SGD","LU1989772840.SGD","LU0225283273.USD","LU0314104364.USD","LU2089284900.SGD","LU2347655156.SGD","LU1244550221.USD","USA","LU1791710582.SGD","LU1548497426.USD","LU0006306889.USD","BK4516","LU0528227936.USD","LU1989772923.USD","LU2028103732.USD","LU0158827781.USD","BK4534","LU0234570918.USD","LU1732799900.SGD","LU2023251221.USD","BK4139","LU0267386448.USD","LU1668664300.SGD","LU1244550577.SGD","LU2133065610.SGD","LU0320765646.SGD","LU2111349929.HKD","BK4585","LU0795875169.SGD","LU1363072403.SGD","LU1720051108.HKD","LU1720051017.SGD","BK4127","LU0158827948.USD","BCAX","LU2089283258.USD","LU1244550494.USD","LU0882574139.USD","LU1732800096.USD","IE00BKVL7J92.USD","LU2271345857.HKD","IE00BZ1G4Q59.USD","LU0098860793.USD","LU0971096721.USD","LU0106831901.USD","LU0557290698.USD"],"gpt_icon":0},{"id":"2614725838","title":"Bicara Therapeutics announces proposed offering of $150M in common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2614725838","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614725838?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:35","pubTimestamp":1771968927,"startTime":"0","endTime":"0","summary":"All of the shares of common stock to be sold in the proposed offering will be sold by Bicara. Morgan Stanley, TD Cowen, BofA Securities, Cantor and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-announces-proposed-offering-of-150m-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-announces-proposed-offering-of-150m-in-common-stock-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1791710582.SGD","BK4588","LU1363072403.SGD","LU1720051108.HKD","IE00BZ1G4Q59.USD","LU1668664300.SGD","LU2023251221.USD","BK4516","BK4581","BK4127","IE00BKVL7J92.USD","LU2028103732.USD","LU2357305700.SGD","LU1791710400.SGD","LU2271345857.HKD","BK4139","LU2111349929.HKD","LU0971096721.USD","LU0795875086.SGD","BK4504","LU0528227936.USD","LU1162221912.USD","LU0320765646.SGD","LU1732799900.SGD","BCAX","LU2089284900.SGD","LU2347655156.SGD","LU0158827781.USD","LU1989772923.USD","LU0106261372.USD","LU1720051017.SGD","LU0912757837.SGD","LU0098860793.USD","LU1244550221.USD","LU1989772840.SGD","LU1548497426.USD","LU0557290698.USD","LU0234570918.USD","BK4585","LU0882574139.USD","LU0106831901.USD","BK4534","LU0225283273.USD","LU0158827948.USD","LU0795875169.SGD","LU1074936037.SGD","LU1244550494.USD","LU1732800096.USD","LU0314104364.USD","LU0267386448.USD"],"gpt_icon":0},{"id":"2614405497","title":"BRIEF-Bicara Therapeutics Announces Proposed Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2614405497","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614405497?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:02","pubTimestamp":1771966978,"startTime":"0","endTime":"0","summary":"BRIEF-Bicara Therapeutics Announces Proposed Public Offering of Common StockFeb 24 (Reuters) - Bicara Therapeutics Inc BCAX.O:BICARA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCKBICA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA58GYZY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2613171125","title":"Bicara Therapeutics Publishes Corporate Presentation on FICERA EGFR-Directed Antibody With TGF-β Ligand Trap in HPV-Negative HNSCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2613171125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613171125?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:06","pubTimestamp":1771938400,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Publishes Corporate Presentation on FICERA EGFR-Directed Antibody With TGF-β Ligand Trap in HPV-Negative HNSCC. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on February 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL4VDrNK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2613787777","title":"Bicara Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613787777","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613787777?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:30","pubTimestamp":1771853400,"startTime":"0","endTime":"0","summary":"BOSTON, Feb.  23, 2026  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3242627/0/en/Bicara-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2613627693","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Accendra Health (ACH) and Travere Therapeutics (TVTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613627693","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613627693?lang=en_us&edition=fundamental","pubTime":"2026-02-23 02:20","pubTimestamp":1771784413,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bicara Therapeutics Inc. (BCAX – Research Report),...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-bicara-therapeutics-inc-bcax-accendra-health-ach-and-travere-therapeutics-tvtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-bicara-therapeutics-inc-bcax-accendra-health-ach-and-travere-therapeutics-tvtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4588","XLV","LU0128526141.USD","TVTX","XBI","BK4139","LABU","BK4153","BK4137","BK4175","BK4581","LU0029874061.USD","ACH","BK4585","HCSG"],"gpt_icon":0},{"id":"2613763032","title":"Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Guardant Health (GH) and Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613763032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613763032?lang=en_us&edition=fundamental","pubTime":"2026-02-23 02:10","pubTimestamp":1771783853,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MoonLake Immunotherapeutics (MLTX – Research Report)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-guardant-health-gh-and-bicara-therapeutics-inc-bcax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moonlake-immunotherapeutics-mltx-guardant-health-gh-and-bicara-therapeutics-inc-bcax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","HCSG","LU0029874061.USD","BK4139","BK4551","BK4585","BK4588","MLTX","BCAX","BK4137","BK4196","GH","LABU","LU0128526141.USD","XBI","BK4535","XLV"],"gpt_icon":0},{"id":"2612230889","title":"Bicara: Best-in-Class Potential for Ficerafusp Alfa in First-Line HPV-Negative Head and Neck Cancer Supports Buy Rating and $30 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2612230889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612230889?lang=en_us&edition=fundamental","pubTime":"2026-02-20 09:25","pubTimestamp":1771550721,"startTime":"0","endTime":"0","summary":"Analyst Soumit Roy from JonesTrading maintained a Buy rating on Bicara Therapeutics Inc. and keeping the price target at $30.00. Soumit Roy has giv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/bicara-best-in-class-potential-for-ficerafusp-alfa-in-first-line-hpv-negative-head-and-neck-cancer-supports-buy-rating-and-30-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/bicara-best-in-class-potential-for-ficerafusp-alfa-in-first-line-hpv-negative-head-and-neck-cancer-supports-buy-rating-and-30-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2612397192","title":"BRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2612397192","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612397192?lang=en_us&edition=fundamental","pubTime":"2026-02-20 06:46","pubTimestamp":1771541172,"startTime":"0","endTime":"0","summary":"BRIEF-Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses In 1L R/M HPV-Negative HNSCCFeb 19 (Reuters) - Bicara Therapeutics Inc BCAX.O:FICERAFUSP ALFA 2000MG Q2W DEMONSTRATES DEEP, DURABL","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nFWN3ZF1CF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2612394052","title":"Bicara announces promising Phase 1b ficerafusp alfa results","url":"https://stock-news.laohu8.com/highlight/detail?id=2612394052","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612394052?lang=en_us&edition=fundamental","pubTime":"2026-02-20 06:32","pubTimestamp":1771540360,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. ( ($BCAX) ) has issued an update. On February 19, 2026, Bicara Therapeutics reported preliminary results from an explorato...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicara-announces-promising-phase-1b-ficerafusp-alfa-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicara-announces-promising-phase-1b-ficerafusp-alfa-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2612235184","title":"Bicara Therapeutics Inc. Publishes Oral Presentation on Ficerafusp Alfa Plus Pembrolizumab in HPV-Negative Recurrent or Metastatic HNSCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2612235184","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612235184?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:36","pubTimestamp":1771536963,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. Publishes Oral Presentation on Ficerafusp Alfa Plus Pembrolizumab in HPV-Negative Recurrent or Metastatic HNSCC. Bicara Therapeutics Inc. published a medical research presentation on a clinical study evaluating ficerafusp alfa  in combination with pembrolizumab for HPV-negative first-line recurrent or metastatic head and neck squamous cell carcinoma. The document outlines the study rationale and mechanism of action involving dual targeting of TGF-β and EGFR, describes unmet need and outcomes benchmarks from prior data sources, and summarizes objectives related to tumor microenvironment effects and dosing schedule feasibility. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL48CY40:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2612235318","title":"Ficerafusp Alfa 2000Mg Q2w Demonstrates Deep, Durable Responses in 1L R/M Hpv-Negative Hnscc and Supports Development of Less Frequent Dosing Regimen","url":"https://stock-news.laohu8.com/highlight/detail?id=2612235318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612235318?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:30","pubTimestamp":1771536644,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nFWN3ZF1CF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2612235315","title":"Bicara Therapeutics Inc:  Plans to Develop a Loading and Every-Three-Week Maintenance Regimen for Ficerafusp Alfa, Pending Regulatory Alignment","url":"https://stock-news.laohu8.com/highlight/detail?id=2612235315","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612235315?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:30","pubTimestamp":1771536644,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nFWN3ZF1CF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":104,"code":"91000000","status":"200"}]}}